Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 May 2;193(3):565–582. doi: 10.1083/jcb.201010065

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 Raleigh et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 6. — CK2-mediated barrier regulation requires ZO-1 and claudin-2. (A and B) TER and PNa⁺/PCl⁻ responses of control and occludin knockdown monolayers to CK2 inhibition. (C and D) TER and PNa⁺/PCl⁻ responses of control and ZO-1 knockdown monolayers to CK2 inhibition. (E) TER and PNa⁺/PCl⁻ after claudin-1 and claudin-2 knockdown. (F and G) TER and PNa⁺/PCl⁻ responses of control and claudin-2 knockdown monolayers to CK2 inhibition. (H and I) TER and PNa⁺/PCl⁻ responses of control, claudin-1, claudin-2, and double-knockdown monolayers to CK2 inhibition. (J) Tight junction protein expression in Caco-2 and T84 monolayers, before or after 12 h of IL-13 treatment (1 ng/ml). (K and L) Effect of CK2 inhibition (50 µM TBCA) on TER and PNa⁺/PCl⁻ of control and IL-13–treated T84 monolayers.